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ABSTRACT 
 
Introduction. Early diagnosis of sepsis allows to make a diagnosis on time, 
correctly assess the condition of young children, and start timely treatment. The 
article analyzes the diagnostic potential of new early marker like procalcitonin. 
Material and methods. The research involved 82 children with the diagnosis of 
sepsis, severe sepsis, or septic shock, who were under observation in the Tashkent 
Medical Academy. The study population constituted all children from newborns to 
3 years old patients. All patients were divided into documented bacterial (n=22) 
versus abacterial inflammation (n=60) infections in order to assess serum PCT 
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concentrations with a cutoff value of >0.5 ng/mL.  The traditionally widely used 
biomarkers of sepsis are cytokines, CRP and PCT. Results and discussion. In the 
process of sepsis monitoring, procalcitonin unlike other markers, reliably reflects 
the real dynamics of its severity, quickly and adequately changes depending on the 
effectiveness of therapy, predicts relapses of sepsis after remission, when the 
clinical signs of sepsis and procalcitonin levels normalize. With surgical 
pathology, injuries and burns in the absence of an infection, procalcitonin does not 
increase. Early diagnosis of sepsis is difficult issue in pediatric practice, whilst it 
can be vital for positive patient outcomes in sepsis management. Any delay in 
diagnosis and treatment may bring on multiple organ failure and can be hazardous 
with elevated mortality consequences. Early diagnosis and effective management 
of sepsis not only gives an opportunity for prompt antibiotic therapy and a 
potential decrease in mortality, it can also belittle the unnecessary use of 
antibiotics. Conclusion. A review of the results of international and domestic 
studies suggest that procalcitonin is an effective method for the early diagnosis and 
monitoring of systemic infections of young children. 
 
KEY WORDS: sepsis, severe sepsis, septic shock, procalcitonin, presepsin, 
calcitonin, biomarker. 
 
THE LIST OF ABBREVIATIONS 
SIRS - Systemic Inflammatory Response Syndrome 
SARS- Severe Acute Respiratory Syndrome 
ICU- intensive care unit 
PCT- procalcitonin 
WHO- World Health Organization 
CRP-C-reactive protein 
WBC-white blood cells 
C-GRP-calcitonin gene related peptide 
CALC-1-calcitonin gene-related peptide and katacalcin 
mRNA- Messenger RNA 
SCCM-Society of Critical Care Medicine 
ESICM- European Society of Intensive Care Medicine 
TNF-alpha-Tumour Necrosis Factor alpha 
IL-10-Interleukin 10 
IL-6-Interleukin 6 
CVD-Cardiovascular disease 
PSP-Presepsin 
AUC-Area under the Curve 
ROC-Receiver operating characteristic 
NTO-National Transplant Organization 
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APACHE II-Acute Physiology and Chronic Health Evaluation II 
MEDS-Medical Emergency Distribution System 
SOFA score-The sequential organ failure assessment score 
iRA-infectious RA 
fRA-flare RA-without infection 
SBP-Spontaneous bacterial peritonitis 
AKI-acute kidney injury 
GFR-glomerular filtration rate 
PVVHF-prolonged veno-venous hemofiltration  
LPS-Lipopolysaccharides 
 
INTRODUCTION 
Sepsis (Systemic Inflammatory Response Syndrome) is considered to be one 
of the most common reasons of inpatient death. The number of hospitalizations for 
sepsis per 100,000 people increased from 143 in 2000 to 343 in 2007 [1]. 
Epidemiological studies conducted in Europe (EPISEPSIS) and Australia 
(ANZICS) showed that the frequency of Systemic Inflammatory Response 
Syndrome (SIRS) in developed industrial countries is 50–100 cases per 100,000 
populations. The frequency of Severe Acute Respiratory Syndrome (SARS) in 
intensive care units is about 18%, as well as, septic shock is about 3-4% [2]. The 
incidence rate is currently not tending to decrease and incidence hospital infections 
increase annually by 3–9%. In this case, mortality reaches 19–40% with severe 
sepsis, and 70% with septic shock [3,4]. Surgical sepsis accounts for 30% of all 
cases [5] and is the leading cause of death in surgical wards intensive care unit 
(ICU). The development of septic shock during planned surgical interventions, 
mortality reaches 30%, and in emergency - from 39% [6,7]. Prompt diagnosis and 
treatment of neonatal early-onset sepsis are crucial to prevent severe morbidity and 
mortality [8]. However, the initial, clinical presentation is often subtle and 
nonspecific, and commonly used biomarkers have low predictive values for early 
sepsis, which presents a daily challenge to clinicians involved in neonatal care [9]. 
Over the years, there has been an urgent need to find a sufficiently sensible and 
specific laboratory biomarker, which could allow distinguishing between a non-
infectious SIRS and sepsis. One of these biomarkers is undoubtedly procalcitonin 
(PCT).  PCT has the highest negative predictive value (87–100%) of all established 
biomarkers for severe, invasive bacterial infections in neonates. PCT seems to be 
the best intervention to reduce duration of antibiotic treatment in neonates 
suspected of early-onset sepsis, because PCT has the highest negative predictive 
value of all established biomarkers for infection [10,11]. The interpretation of PCT 
values in neonates is complicated by a physiological increase up to 48 h 
postpartum, and other perinatal factors—such as chorioamnionitis, hypoxaemia, 
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perinatal asphyxia, and maternal pre-eclampsia—can also cause it to increase [12]. 
Reference values of PCT in neonates with and without early-onset sepsis have 
been established [13,14]. PCT-guided decision making has been used to safely 
reduce antibiotic treatment in critically ill adults and children with suspected or 
proven invasive bacterial infections [15,16]. Compliance with antimicrobial 
stewardship is difficult to obtain and rarely reported in neonatology. In this era of 
globally increasing antibiotic resistance rates, World Health Organization (WHO) 
have highlighted the urgent need for enhanced antimicrobial stewardship to 
address this issue [17-21]. Increasing evidence suggests, however, that every dose 
of antimicrobial therapy counts in the emergence of antimicrobial resistance and in 
changing the human microbiome, and other evidence suggests that changes in the 
microbiome in early life are particularly important in shaping the individual’s 
immune system and future health [22-25]. It is also one of the leading causes of 
death among critically ill patient [26]. Out of 60 clinical trials that have studied the 
utility of serum PCT levels for establishing an infectious cause of sepsis, 58 
resulted in positive results, and 2 was negative [27]. It is important to identify 
prognostic factors early as this may necessitate modification of further 
management. PCT is a precursor of the hormone calcitonin, and is increased early 
in sepsis and falls rapidly with therapy [28]. PCT has been used in the pediatric 
population to differentiate sepsis from other non-septic causes of fever/SIRS [29-
33]. The past century has witnessed a rising trend in the incidence of infections, 
sepsis, and septic shock regardless of overwhelming development in treatment 
modalities [34]. Diagnosis is optimized by using biochemical tests for sepsis, such 
as C - reactive protein (CRP) or white blood cells (WBC) which have reportedly 
low diagnostic accuracy and are at times ambiguous [35]. PCT has been used as 
marker of sepsis with sensitivity and specificity of 83% and 62% respectively with 
significantly high levels in the patients having sepsis and positive blood culture 
results than with culture negative results [36,37].  PCT is a glycoprotein present in 
C cells of thyroid gland. It belongs to the group of related peptide (C-GRP) 
encoded by the CALC-1 gene and is formed from the common precursor pre-
calcitonin [38]. In healthy subjects, CALC-1 genes synthesize Calcitonin, but 
presence of microbial infection through endotoxin or pro-inflammatory cytokines 
increases calcitonin gene expression and PCT mRNA is mostly synthesized. This 
leads to release of PCT from all parenchymal tissue, exclusively in response to 
bacterial infection only and not viral or inflammatory disease. PCT has a 
disintegration of ~22–29 h and, during bacterial infections, its levels start to rise 4 
h after onset and reach the peak between 12 and 24 h, earlier than C-reactive 
protein (CRP), which peaks after 2–3 days [39,40]. This makes PCT to be a 
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specific diagnostic marker to detect bacterial sepsis. On the other hand, serum 
levels of PCT increase briskly within 2–6 h after the stimulus making it a rapid 
diagnostic marker compared to culture [41,42].  
Both sepsis and septic shock are major health care problems, affecting 20 to 
30 million people every year worldwide, with mortality ranging from 10% to 60% 
with increasing disease severity [43]. The effect of sepsis treatment is extremely 
time dependent. Survival chance of patients is maximized if antibiotics are 
administered within 1 h from clinical presentation and each hour of delay in 
antibiotic administration results in a significant increase of mortality for septic 
shock [44]. In 2016, Society of Critical Care Medicine (SCCM) and the European 
Society of Intensive Care Medicine (ESICM) jointly proposed a new definition of 
sepsis as a “life-threatening organ dysfunction caused by a dysregulated host 
response to infection”. It is important to be able to formulate and recognize the 
clinical presentation of sepsis, although consideration of serum biomarkers is also 
a key component of formulating a definitive diagnosis. Therefore, the purpose of 
this research is to analyze the clinical use of PCT as a biomarker of sepsis.  
 Materials and methods.   
This research is an experimental study which was performed for the period 
from 2017 to 2019. 82 children were observed with the diagnosis of sepsis, severe 
sepsis, or septic shock in the Tashkent Medical Academy. The study population 
constituted all children from newborns to 3 years old patients. All patients were 
divided into documented bacterial (n=22) versus abacterial inflammation (n=60) 
infections in order to assess serum PCT concentrations with a cutoff value of >0.5 
ng/mL.  The traditionally widely used biomarkers of sepsis are cytokines, CRP and 
PCT. Numerous studies have shown that the earliest increase in the development 
of both systemic infections and in “sterile” inflammations is demonstrated by such 
pro-inflammatory cytokines as TNF-alpha, IL-10 and IL-6, whose levels peak in 
2–4 hours. After this, the level of PCT begins to increase, which reaches a 
maximum after 8-12 hours and then, if the inflammation is “sterile”, decreases, and 
if a systemic infection develops, it rises, and then, depending on the dynamics of 
sepsis, it rises or decreases. After this, the main early marker of the acute phase of 
inflammation, both “sterile” and infectious - CRP, begins to rise, which reaches a 
peak after 12-24 hours. Until recently, PCT was considered the most specific 
marker of sepsis. However, problems associated with the use of PCT include:  
1) a large "gray zone" of uncertainty in which the levels of PCT are (ng / 
ml): a) with CVD (cardiovascular disease) without infection - below 1.0; b) with 
local bacterial infections without systemic manifestations - 0.3–1.5; c) in severe 
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viral infections - 0.5–2.0 (in all these cases, the diagnosis of sepsis cannot be made 
with confidence, it is recommended to repeat the measurements after 6-24 hours); 
2) an increase that is nonspecific with respect to infection within 24–48 
hours in conditions associated with massive tissue damage: surgery, burns, 
injuries; 
3) an increase that is nonspecific with respect to infection in newborns in the 
first 48 hours of life; 
4) the long disintegration of PCT (25-30 hours) complicates the operational 
monitoring of sepsis. 
A list of conditions associated with a “non-infectious” increase in PCT is 
given in reviews [45-50]. This review analyzes the results of studies published in 
1996–2011, and on the effectiveness of PCT for diagnosis and monitoring and 
sepsis. The authors draw the following conclusions; there must be established 
diagnostic levels of PCT for differentiation between CVD, sepsis and severe 
sepsis. 
For the diagnosis of sepsis: 
• At a borderline level of PSP 317 pg / ml, the sensitivity was 70.8%, 
specificity - 85.8%, positive predictive value - 92.3%, negative - 51.5%. 
• At the borderline level of PCT 0.25 ng / ml, the sensitivity was 60.0%, 
specificity - 77.7%, positive predictive value - 92.8%, negative - 28.4%. The 
values of AUC ROC for the diagnosis of sepsis were: for PSP - 0.820, for PCT - 
0.724. 
For the diagnosis of severe sepsis: 
• At the borderline level of PSP 449 pg / ml, the sensitivity was 82.4%, 
specificity - 72.4%, positive predictive value - 71.3%, negative - 83.2%. 
• At the borderline level of PCT of 1.435 ng / ml, the sensitivity was 52.0%, 
specificity - 79.8%, positive predictive value - 69.6%, negative - 65.1%. The AUC 
ROC values for SRP were 0.840, for PCT - 0.741. 
For the diagnosis of septic shock: 
• At the borderline level of PSP of 550 pg / ml, sensitivity is 85.7%, 
specificity is 63.6%, positive predictive value is 28.5%, and negative is 96.3%. 
• At the borderline level of PCT 4.415 ng / ml, sensitivity - 54.1%, 
specificity - 81.1%, positive predictive value - 34.2%, negative - 90.7%. 
The AUC ROC values for PSP were 0.790, for PCT - 0.768, but the 
differences between these indicators were statistically unreliable. 
Thus, “in the early stages of the development of systemic infection, PSP is 
the most sensitive and specific marker of sepsis, reflecting its dynamics, severity of 
the patient’s condition, and predicting outcomes”. 
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Research results and discussion. 
Despite the fact that high levels of PCT indicate a systemic bacterial 
infection (unlike the viral, fungal, or inflammatory etiology of sepsis), serum levels 
of PCT do not correlate with the severity of sepsis or mortality. Thus, at present, 
the serum levels of PCT used to assess the effectiveness of antibiotic therapy and 
formulate a decision on the feasibility of increasing (decreasing) its intensity have 
only research applications. Nevertheless, serum concentrations of PCT are 
important: a) for monitoring the clinical consequences of medical and surgical 
therapy for sepsis; b) to observe the development of CVD in burn patients and ICU 
patients; c) may play a role in reducing the intensity of antibiotic therapy. 
 In general, it is noted that the main problem associated with the use of PCT 
is its diagnostic uncertainty in the first few days, when its "non-infectious" increase 
can occur. Therefore, PCT has a lower diagnostic value precisely when this value 
has the highest price. Presepsin (PSP) is a circulating protein which concentration 
in the blood increases rapidly with the development of systemic infections, sepsis, 
severe sepsis and septic shock. An increase in PSP levels to a greater extent than 
an increase in PCT levels is associated with an increase in the severity of systemic 
infection. An increase in PCT occurred mainly in severe sepsis and septic shock. 
In a preliminary study (n=146), it was shown that for detection of sepsis on 
the day of admission to NTO with signs of CVD, the values of  AUC ROC were: 
for PSP -  0.878, for PCT - 0.668 and for APACHE II - 0.815 [51]. 
For stratification of patients entering ONT, the following boundary values of 
the initial levels of PSP (ng / ml) were proposed: 
• <200 - very low risk of developing sepsis; 
• 200–300 - low risk of developing sepsis; 
• 300–500 - moderate risk of developing sepsis; 
• 500–1000 - sepsis; 
• ≥ 1000 - severe sepsis, septic shock. In a multicenter study, it was shown 
that upon admission to ONT (n = 93), the boundary levels of PSP (ng / ml, median) 
and PCT (ng / ml, median) were: 
• with acute symptoms of CVD: PSP - 517; 
FCT - 1.0; 
• with sepsis: PSP - 875, PKT - 9.0; 
• in severe sepsis and septic shock: PSP - 1460; FCT - 19.0. 
It is very significant that in patients with an established diagnosis of 
infection, the PSP level was maximum at admission (T0) compared with that after 
24 hours (T1) and 72 hours (T2), while the maximum level of PCT was observed 
after 24 h (T1). 
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At the same time, the boundary value of PSP for the detection of sepsis was 
600 pg / ml; sensitivity - 78.95%, specificity - 61.9%; for FCT - 0.18 ng / ml, 
sensitivity - 89.47%, specificity - 75.90%. 
In another study, patients (n = 226) who were admitted to ONT with signs of 
CVD were also observed. Measurements were taken immediately upon post-
exposure. In 37 patients, blood cultures were subsequently positive. 
The diagnostic characteristics of the PSP and PCT were: 
• PSP, borderline level - 729 ng / ml, sensitivity - 81.1%, specificity - 63.0%: 
positive predictive value - 30.0% negative - 94.4%, AUC ROC - 0.750; 
• PCT, borderline level - 0.45 ng / ml, sensitivity - 75.7%, specificity - 
64.0%, positive predictive value - 29.2%, negative - 93.1%, AUC ROC - 0.785. 
When observing patients (n=68) who were admitted to the ICU with clinical 
signs of sepsis, for the detection of sepsis, the AUC ROC values were 0.775 for 
PSP and 0.712 for PCT [52]. 
Patients entering ONT, as a rule, represent a very clinically heterogeneous 
group of patients with various acute pathologies and complications of both an 
infectious and non-infectious nature. 
In a study of patients (n=114) who entered 117 different NTOs and did not 
have acute infectious pathologies, it was found that the PSP levels were: for men 
(pg / ml, median) - 443 (343–563) and for women 430 (337–561) [53]. Patients 
older than 70 years had elevated PSP levels compared to younger patients and 
amounted to (pg / ml, median) 470 (380–602 versus 300 (201–457). Also, PSP 
levels were slightly increased in patients with reduced GFR. 
When observing 69 patients, it was found that 41 patients had sepsis, and 3 
patients (7.3%) died; 18 - severe sepsis, 8 patients died (44.4%); 10 - septic shock, 
8 patients died (80%) [54]. The total 30-day mortality rate was 27.5%. PSP levels 
with high reliability discriminated patients with both favorable and unfavorable 
outcomes, and outcomes of varying severity (placement in ICU, mechanical 
ventilation, dialysis). 
The AUC ROC values were: 
• to predict mortality: for APACHE II - 0.835; for PSP - 0.833; for PCT - 
0.568; 
• to predict the severity of outcomes among survivors: for APACHE II - 
0.923; for PSP - 0.796; for PCT - 0.624. 
In a multicenter study, which included monitoring patients (n = 106) who 
received ONT with signs of CVD, it was shown that elevated PSP levels on 
admission predicted 60-day survival, while PCT levels did not have such 
predictive ability [55]. So, upon admission, the initial mean PSP level of 4232.4 pg 
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/ ml was associated with mortality, and 3451.2 pg / ml with survival. The PCT 
levels measured on the first and second day did not have predictive value. 
In another multicenter study of patients admitted to ICU with sepsis and 
septic shock (n = 100), it was shown [56]: 
• the PSP level (pg / ml, median), which was 2269 (1171–4300) on the first 
day, was associated with 28-day mortality, and the level of 1184 (875–2113) was 
associated with survival. 
• the level of PCT (ng / ml, median), which amounted to 18.5 (3.4–45.2) on 
the first day, did not have prognostic characteristics. 
Predictive efficacy (AUC ROC) for PSP was: on the first day, 0.69; in the 
second - 0.70; on the seventh day - 0.74, for PCT - 0.56; 0.55 and 0.64, 
respectively. The predictive efficacy of the SOFA scale on these days was 0.69; 
0.65 and 0.75, respectively. 
SRP in monitoring sepsis therapy. The marker of disintegration is crucial 
for the speed of sepsis monitoring. If this time is large, the concentration of the 
marker will not reflect the current sepsis severity, but that which was in the past. 
During intravenous injection of the PSP preparation to laboratory animals and 
recording its determination in urine, it was found that disintegration in circulation 
is from 30 minutes to 1 hour. Recall that the half-life of PCT is 25–30 hours. 
However, in the group with an unfavorable prognosis, there was also a 
decrease in the levels of PCT, IL-6 and CRP, but not PSP. At the same time, the 
duration of antibiotic therapy in the group with an unfavorable prognosis was 
higher, and the 28-day mortality rate was higher. 
According to SOFA, the average values of the levels of PSP, PCT, IL-6 and 
CRP during monitoring of sepsis with a favorable prognosis (7.0 points) and with 
an unfavorable (9.0 points) were: 
• PCT (ng / ml, median), favorable prognosis - 27.3, unfavorable - 16.2 
(decrease by 40%); 
• IL-6 (pg / ml), favorable prognosis - 1972, non-favorable - 1555 (decrease 
by 8%); 
• CRP (mg / l), favorable prognosis - 137.0, non-favorable - 121.0 (decrease 
by 12%); 
• PSP (pg / ml, median), favorable prognosis - 1512, unfavorable - 1539 
(increase by 2%). 
As indicated, since PSP is induced during phagocytosis of bacteria 
independently of LPS and cytokines, the mechanism of production of PSP is 
different from that of those for IL-6, PKT and SRB. The authors suggest that “PSP 
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can reflect the severity of infection to a greater extent than the severity of the 
inflammatory response”. 
The results of monitoring PSP and PCT in 9 patients who underwent therapy 
for nosocomial infections, and in whom remission was observed with a subsequent 
relapse, turned out to be very important. 
In 7 (77.8%) patients who were diagnosed with severe sepsis upon 
admission, at the initial stage of infection, the PSP level was > 1000 pg / ml and 
remained high all the time, despite antibiotic therapy, the disappearance of 
symptoms of sepsis and the normalization of PCT levels. 
It should be emphasized once again that in patients who had a relapse of 
sepsis, PSP levels remained high (> 1000 pg / ml), and PCT levels decreased 
during remission and then increased again with sepsis. It is significant that in 9 
patients with recurrence of sepsis and high PSP during clinical remission in 
samples of rectal contents in large amounts was found to be Klebsiella pneumonia. 
In general, the authors believe that “this study confirms the importance of 
monitoring sepsis using a combination of different markers in order to get a 
reliable diagnosis. Maximum presepsin levels can give the clinician an alarm so 
that he does not cancel antibiotic therapy and carefully monitors the health status 
of the septic patient even after the clinical symptoms disappear and the PCT levels 
return to normal” [57]. 
Patients with NTO and ICU are very often on mechanical ventilation. 
Patients (n = 120) who were admitted to ICU with acute pathologies and 
needed mechanical ventilation were observed [58]. During the observation, 38 
(31.7%) patients died, 16 (13.3%) developed sepsis, 9 patients with sepsis died. 
PSP measurements were carried out immediately after intubation, before turning 
on the ventilator, after extubation, and before discharge from the ONT. The 
average values of PSP (ng / ml) for differentiation between septic patients and 
aseptic patients were 1098 (886–1263) and 3185 (1734–3904), respectively. The 
optimal borderline level for detecting the development of sepsis with mechanical 
ventilation is 1965 ng / ml, sensitivity - 85.7%, specificity - 84.0%. In the absence 
of sepsis, PSP remained below 1600 ng / ml. 
The results of studies on the diagnostic role of PSP in the development of 
severe infectious complications associated with diseases of various etiologies are 
very indicative. 
Cases associated with rheumatoid arthritis. The study included patients (n 
= 25) with rheumatoid arthritis (RA) complicated by bacterial infection, 34 patients 
with severe RA and 34 healthy individuals. Patients with RA in whom the 
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pathogen was identified were identified as iRA (infection); patients with severe 
RA, but without infection, like fRA. 
 The levels of PSP (PG / ml) were at iRA - 2088.4 ± 4243.7; at fRA - 319.3 
± 321.8 pg / ml; in the control, 136.0 ± 57.0. At iPA, PSP correlated with CRP 
levels; at fPA, it did not correlate. Significantly, with iRA therapy, PSP and CRP 
levels decreased, and with fRA therapy, CRP decreased, but not PSP levels. 
The diagnostic effectiveness of PSP for the diagnosis of infectious RA 
according to AUC ROC values was 0.817, which indicated "the effectiveness of 
measuring PSP levels for the diagnosis of infectious rheumatoid arthritis". 
Cases associated with cirrhosis. Patients (n = 25) with cirrhosis were 
observed, measurements were performed to detect bacterial infection upon 
admission and to monitor therapy after 48, 96 and 144 hours and after 15 days. In 
16 patients, PSP levels (pg / ml, average) were 1854 ± 1744. After 72 ± 4.8 hours, 
microbiological tests confirmed the presence of infections in all 16 patients. When 
monitoring in 5 (31%) patients after 24 and 48 hours, the PSP remained 
unchanged, these patients did not respond to empirical antibiotic therapy, after 
receiving the results of the antibiogram, the therapy was changed. The authors 
suggest that “measuring PSP levels is 100% specific to blood cultures and can be 
used to identify infectious complications of liver cirrhosis and monitor its therapy”. 
Cases associated with spontaneous bacterial peritonitis (SBP) is the most 
frequent and dangerous complication in patients with cirrhosis associated with 
viral hepatitis C. Patients (n = 30) with chronic hepatitis with ascites were 
observed, 10 of them (group 1) had sterile ascites, 20 (group II) - SBP. 
Concentrations of PSP (pg / ml, average values) were 148.6 ± 34.9 with sterile 
ascites; with SBP - 3473.0 ± 1911.6; average - 4621.5. In patients with SBP, PSP 
was also measured 10 days after the start of antibiotic therapy, while PSP levels 
were reduced and amounted to an average of 673.4 ± 245.0, median - 3473 ± 
1911.6. Mortality in the group with SBP was 20% (4 cases out of 20), in non-
survivors, the PSP levels were average - 4631, median - 3915. 
Cases associated with pancreatic necrosis. A preliminary study included 
patients (n = 18) with pancreatic necrosis. From the moment of the disease, the 
levels of PSP and PCT were measured in all patients. In 14 patients, PCT increased 
from the 2nd – 5th day of the disease. Eight of these patients had an increase in 
PSP; it was these patients who were subsequently diagnosed with purulent-septic 
complications - pancreatic abscess (n = 2), pancreatic phlegmon (n = 2), 
retroperitoneal phlegmon (n = 1), pneumonia (n = 4). Clinical signs of these 
complications appeared 1.8 ± 0.3 days later than an increase in PSP. 6 patients with 
elevated PCT and normal PSP showed signs of CVD and intoxication (APACHE 
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II> 24), but without purulent-septic complications. It is believed that “PSP is a 
more sensitive marker of purulent-septic complications of pancreatic necrosis than 
PCT, PSP rises before the clinical manifestations of purulent-septic 
complications”. 
Cases associated with acute kidney damage. Sepsis is the most common 
cause of AKI. Moreover, data is heating up that patients who are in ICU for an 
initially aseptic AKI develop sepsis with a high frequency. It is extremely 
significant that there is a direct correlation between the severity of initial sepsis and 
the severity of subsequent AKI and, conversely, between the severity of initial AKI 
and the severity of subsequent sepsis. The heavier the initial sepsis, the higher the 
risk of developing severe AKI and vice versa. 
When observing patients (n = 144) who received ONT, it was noted that a 
decrease in GFR <60 ml / min / 1.73 m2 was associated with a slightly increased 
PSP (pg / ml) to 470, with GFR ≥ 60 mm / 1 73 m2, the level of PSP was 386 pg / 
ml. 
In another study, septic patients (n = 20) who underwent cardiovascular 
surgery and were on hemodialysis, control (n = 10, healthy individuals) were 
observed for 1 year. PSP levels (pg / ml) in patients with sepsis were 4368 ± 3088 
versus 694.1 ± 239.1 in the control. 
At the same time, the levels of PSP and PCT (ng / ml) did not change after 
hemodialysis. No difference in the PSP and PCT levels between survivors and 
non-survivors was observed PSP - 4184.1 ± 3039.5 versus 4593.5 ± 3316.2; PCT - 
9.66 ± 17.55 versus 14.93 ± 20.54. 
The results of observation of patients (n = 254) who were admitted to ONT 
with suspected sepsis and other diseases, in particular, with acute kidney damage 
(AKI), turned out to be interesting. It turned out that upon admission, PSP levels 
(pg / ml, median) and AUC ROC values were: 
• without sepsis and without AKI (n = 78) PSP - 406 (6–4374); 
• sepsis without AKI (n = 37) - 1065 (86–9960). AUC ROC - 0.789; 
• AKI without sepsis (n = 14) - 1607 (454–8516); 
• sepsis and AKI (n = 27) - 1523 (293–16764), AUC ROC - 0.593. 
It was concluded that severe renal dysfunction reduces the diagnostic 
accuracy of PSP for the diagnosis of sepsis. 
Then, in the continuation of the previous study, patients (n = 629) were 
admitted to ONT with suspected sepsis. Patients were divided into two groups - 
with AKI and without AKI. The AUC ROC values for the diagnosis of sepsis for 
PSP and PCT were without AKI - 0.883 and 0.870, respectively; with OPP - 0.669 
and 0.804. However, after normalizing (dividing) the AUC ROC values of the AKI 
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+ sepsis group by creatinine levels, the AUC ROC values began to be 0.828 and 
0.852, respectively. The authors suggest that “the optimal borderline levels of PSP 
and PCT for the diagnosis of sepsis in patients with acute renal failure are 409 pg / 
ml / creatinine for PSP, sensitivity - 66.0%, specificity - 91.7%, and for PCT - 1.5 
ng / ml / creatinine (sensitivity - 63.5% and specificity - 95.8%), respectively. 
It is significant that problems with the diagnosis of sepsis in AKI also exist 
in PCT. A recent meta-analysis (201 studies, n = 803, 255 episodes of bacterial 
infection) showed that the total sensitivity of PCT for the detection of sepsis in 
severe renal dysfunction is 73% (54–86%), and for CRP - 78% (52–83%), and the 
total specificity for PCT is 88 % (79– 83%) and for CRP - 84% (52–86%). It is 
believed that “for the diagnosis of systemic infection in patients with kidney 
damage, PCT and CRP have low sensitivity, but acceptable specificity. Given the 
low negative predictive value of these markers, their suitability for eliminating 
sepsis in AKI remains open to question”. 
Moreover, for the diagnosis of sepsis with renal dysfunction, higher border 
levels are also needed, as in surgery. So, when observing patients (n = 276) who 
underwent elective cardiac surgery, 67 were infected, and 75 (27%) had renal 
dysfunction. In patients with infection, PCT was increased, but it was even higher 
with infection and renal dysfunction at the same time. For patients with infection 
only, the borderline level of PCT (ng / ml) was 0.80; with infection and renal 
dysfunction, 2.57. 
In a recent meta-analysis of the registers (n = 1331), it was found that 
borderline PCT levels for sepsis increase with decreasing GFR. So, the average 
PCT values (ng / ml) for the detection of sepsis (positive blood cultures) were: 
• with GFR ≥ 60 ml / min (n = 836) - 1.7 ± 6.8, 
boundary level - 0.37; 
• with GFR 30 - <60 (n = 481) - 6.6 ± 17.5, limited 
personal level - 1.06; 
• with GFR <30 (n = 497) - 12.6 ± 25.9, border- 
the lowest level is 2.50. 
Thus, taking into account that in patients with ONT and ICU very often 
there are impaired renal function, in the diagnosis of sepsis it is necessary to take 
into account the quantitative indicators of these disorders. Unfortunately, there are 
no clear and agreed recommendations on how to do this yet. Studies of the 
diagnostic utility of PSP to assess the risk of developing sepsis with renal 
dysfunction have practical and scientific significance that can hardly be 
overestimated. 
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The development of renal dysfunction is one of the reasons for the need for 
extracorporeal purification methods for hemocorrection in septic patients. 
The effectiveness of prolonged veno-venous hemofiltration (PVVHF) is 
highly dependent on the on-time diagnosis of sepsis and, in particular, on the 
timeliness of indications to its onset. Some sepsis markers have a theoretical 
potential. 
Removal from the vascular bed through the hemofilter membrane. In this 
regard, at the very early stages of intensive care, difficulties may arise in 
interpreting the result of monitoring sepsis. LPS plays a crucial role in the 
pathogenesis of sepsis and multiple organ failure, which requires the development 
of specific and nonspecific methods for its removal from the vascular bed, 
reduction of its endogenous production and translocation of endotoxin. Indications 
for the use of LPS sorption are based on high values of lipopolysaccharidemia with 
the effectiveness of surgical debridement of the focus or foci of infection. 
PCT has developed as an ideal biomarker for sepsis and early detection of 
bacteremia. Early diagnosis of sepsis is difficult issue in pediatric practice, whilst it 
can be vital for positive patient outcomes in sepsis management. Any delay in 
diagnosis and treatment may bring on multiple organ failure and can be hazardous 
with elevated mortality consequences. Early diagnosis and effective management 
of sepsis not only gives an opportunity for prompt antibiotic therapy and a 
potential decrease in mortality, it can also belittle the unnecessary use of 
antibiotics. The study concluded that only 19 (86,3%) of the patients with bacterial 
infections met their cutoff value ( >0.5 ng/mL). PCT can differentiate between 
bacterial infections without etiologic organism and other severe inflammatory 
processes that are also illustrating with an increase of classic inflammatory 
biomarkers, such as CRP, IL-1 and IL-6. 
 Consequently, this data supports the utility of PCT as an effective 
management to establish an adequate diagnosis of sepsis. The study displayed a 
positive correlation between serum PCT concentrations and SOFA scores (p 
=<0.001), illustrating that when the serum PCT concentrations increase, end-
multiorgan failure worsened by APACHE II and the Multiple Organ Dysfunction 
Score. Serum PCT concentrations have been noted in patients that do not have 
sepsis, although concentrations are usually not very high (< 2 ng/mL). 
CONCLUSIONS 
1. PSP is a fundamentally new marker of bacterial and fungal systemic 
infections. 
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2. The mechanism of production of PSP during the induction of sepsis and 
its course differs from that characteristic of traditional sepsis markers, such as 
TNF-alpha, IL-6, IL-10, PCT and CRP. 
3. The mechanism of production of PSP is mainly associated with the 
activation of phagocytosis, the details of this mechanism and the role of PSP in the 
pathogenesis of systemic infections are poorly understood. 
4. With the development of systemic infections, PSP rises earlier than other 
markers of sepsis and regardless of their increase or decrease. 
5. PCT and PSP with 100% reliability, subsequently confirmed by blood 
cultures: 
a) diagnoses sepsis before the manifestation of its clinical symptoms, which 
allows timely initiation of therapy; 
b) predicts favorable and unfavorable outcomes. 
6. When monitoring sepsis, PSP, unlike other markers: 
a) reliably reflects the real dynamics of its severity; 
b) quickly and adequately changes depending on the effectiveness of 
therapy; 
c) predicts the recurrence of sepsis after remission, when the clinical 
characteristics of sepsis and PCT levels are temporarily normalized. 
7. The results of international and domestic studies suggest that PCT and 
PSP is a very effective marker for the early diagnosis and monitoring of systemic 
infections. 
8. Preliminary results suggest that PCT and PSP is a very promising marker 
of extensive infectious complications in diseases of various etiologies. 
9. To have a specific and sensitive biomarker like PCT and PSP would be 
valuable for early diagnosis and management of patients with sepsis in order to 
reduce mortality. 
10. PCT and PSP can be early marker for physicians for reducing the 
duration of antibiotic treatment, minimizing sepsis-associated complications, 
morbidities and deaths as well. 
11. Interpretation of PCT and PSP levels is a navigator for appropriate 
antibiotic therapy. 
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